文献速递淋巴瘤

弥漫大B细胞淋巴瘤一线治疗后完全缓解患者常规临床随访检测复发的获益有限

Limited Benefit of Routine Clinical Follow-Up for Relapse Detection in Diffuse Large B-Cell Lymphoma Patients in Complete Remission Following First-Line Treatment.
PubMed 文献 · Am J Hematol · 2025-01-05

这项基于丹麦淋巴瘤登记处(LYFO)的人群研究纳入2010至2017年诊断的1634例弥漫大B细胞淋巴瘤(DLBCL)患者,其中105例一线R-CHOP类方案后达完全缓解(CR)并随后复发,中位随访6年(范围3-8年)。复发多因症状发现(83%),仅5%的预定常规随访发现复发,而患者主动发起的非预定随访中74%检出复发。作者认为系统性预定监测对早期发现复发的贡献有限,未来应探索替代的复发监测方法。

要点

  • 多数复发为有症状复发(83%),常见表现为B症状和周围淋巴结肿大。
  • 仅5%的预定常规随访导致复发诊断,74%的患者主动非预定随访检出复发。
  • 70%的复发在常规随访之外被识别,无症状复发经体格检查(1%)、血液检查(3%)或影像学(13%)发现。

核心结论

  • 对一线治疗后达完全缓解的DLBCL患者进行系统性预定监测,对早期发现疾病复发的贡献有限。
  • 未来研究应探索替代的复发监测方法,而非仅依赖预先安排的临床随访。

研究设计与样本

  • 基于丹麦淋巴瘤登记处(LYFO)的人群研究,纳入2010至2017年诊断的DLBCL患者共1634例。
  • 其中105例一线R-CHOP类方案后达完全缓解并随后复发,中位随访时间6年(范围3-8年)。

主要发现

  • 多数复发为有症状复发(83%),B症状和周围淋巴结肿大最常见。
  • 无症状复发经体格检查(1%)、血液检查(3%)或影像学发现(13%)识别。
  • 70%的复发在常规随访之外被识别。
  • 仅5%的预定常规随访导致复发诊断,而74%的患者主动发起的非预定随访检出复发。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite advances in treatment, approximately 15% of patients with diffuse large B-cell lymphoma (DLBCL) who achieve complete remission (CR) after first-line therapy will experience a relapse. However, there is no consensus on the optimal follow-up strategies for detecting relapse after achieving CR. This population-based study, based on the Danish Lymphoma Registry (LYFO), identified a total of 1634 patients diagnosed with DLBCL between 2010 and 2017, including 105 patients who achieved CR following first-line R-CHOP-like therapy and subsequently relapsed. The median follow-up time was 6 years (range 3-8 years). Most cases of relapse were symptomatic (83%), with B symptoms and peripheral lymphadenopathy being the most common. Asymptomatic relapses were identified through physical examination (1%), blood tests (3%), or imaging findings (13%). The proportion of relapses identified outside routine visits was 70%. Only 5% of scheduled routine visits led to a relapse diagnosis, whereas 74% of unscheduled visits initiated by the patient outside routine follow-up resulted in relapse detection. Our findings highlight that systematic, scheduled monitoring of patients in remission after first-line treatment contributes only modestly to the early detection of disease recurrence. Future studies should explore alternative methods of relapse surveillance rather than relying solely on pre-scheduled clinical follow-up.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lassen T, Nielsen TH, von Heymann A, et al. Limited Benefit of Routine Clinical Follow-Up for Relapse Detection in Diffuse Large B-Cell Lymphoma Patients in Complete Remission Following First-Line Treatment. Am J Hematol. 2025. PMID: 39757700. doi:10.1002/ajh.27577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。